← Back to Clinical Trials
Recruiting NCT06277401

NCT06277401 Exercise in Patients With Hypermobile Joints and Knee Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06277401
Status Recruiting
Phase
Sponsor University of Southern Denmark
Condition Hypermobility, Joint
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2024-02-21
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Neuromuscular training for the kneeHigh-load strength training for the knee

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2024-02-21 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pain associated with knee joint hypermobility is common in the adult population, but evidence on treatment is sparse. This study investigates if high-load resistance training is superior to usual care in improving activity-related pain in young patients (18-45 years) with hypermobile joints and knee pain.

Eligibility Criteria

Inclusion criteria * Persistent knee pain for ≥ 3 months (self-reported) * Knee pain ≥ 30mm during the last week using a 0-100 mm visual analogue scale (VAS; 0=no pain and 100=worst imaginable pain) (self-reported) * Generalised joint hypermobility assessed with the Five-Part Hypermobility Questionnaire (positive ≥ 2/5) (self-reported) * Local knee joint hypermobility using the passive hyperextension of the knee in standing (positive \> 10 degrees of hyperextension) and confirmed in supine lying (heel resting on 20 cm high block on the bench surface), with passive knee hyperextension (positive \> 10 degrees) (objectively measured) Exclusion criteria * Diagnosed with patellar tendinopathy * Pregnancy or childbirth within the past year (due to increased levels of relaxin that could affect joint stability) * Knee surgery within the past year * Participation in regular structured resistance training within the past six months * Inability to speak and understand Danish. * All types of Ehlers-Danlos syndrome * Other heritable connective tissue disorders such as Marfan syndrome, osteogenesis imperfecta, Loeys-Dietz syndrome, Stickler syndrome, skeletal dysplasias * Autoimmune rheumatic connective tissue disorders such as lupus, rheumatoid arthritis; Chromosomal conditions such as Fragile X syndrome, Kabuki syndrome, Down syndrome * Neuromuscular disorders that can cause joints to become unstable, such as multiple sclerosis

Contact & Investigator

Central Contact

Behnam Liaghat, PhD

✉ bliaghat@health.sdu.dk

📞 +4526826801

Principal Investigator

Behnam Liaghat, PhD

PRINCIPAL INVESTIGATOR

University of Southern Denmark

Frequently Asked Questions

Who can join the NCT06277401 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Hypermobility, Joint. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06277401 currently recruiting?

Yes, NCT06277401 is actively recruiting participants. Contact the research team at bliaghat@health.sdu.dk for enrollment information.

Where is the NCT06277401 trial being conducted?

This trial is being conducted at Odense, Denmark, Odense, Denmark.

Who is sponsoring the NCT06277401 clinical trial?

NCT06277401 is sponsored by University of Southern Denmark. The principal investigator is Behnam Liaghat, PhD at University of Southern Denmark. The trial plans to enroll 90 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology